JP7307059B2 - ガラクトース血症を処置するための組成物および方法 - Google Patents

ガラクトース血症を処置するための組成物および方法 Download PDF

Info

Publication number
JP7307059B2
JP7307059B2 JP2020527861A JP2020527861A JP7307059B2 JP 7307059 B2 JP7307059 B2 JP 7307059B2 JP 2020527861 A JP2020527861 A JP 2020527861A JP 2020527861 A JP2020527861 A JP 2020527861A JP 7307059 B2 JP7307059 B2 JP 7307059B2
Authority
JP
Japan
Prior art keywords
alkyl
galactosemia
halogen
aldose reductase
certain embodiments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020527861A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020528938A (ja
JP2020528938A5 (https=
Inventor
ショーシャナ シェンデルマン，
Original Assignee
アプライド セラピューティクス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アプライド セラピューティクス， インコーポレイテッド filed Critical アプライド セラピューティクス， インコーポレイテッド
Publication of JP2020528938A publication Critical patent/JP2020528938A/ja
Publication of JP2020528938A5 publication Critical patent/JP2020528938A5/ja
Priority to JP2022169791A priority Critical patent/JP7541064B2/ja
Application granted granted Critical
Publication of JP7307059B2 publication Critical patent/JP7307059B2/ja
Priority to JP2024135647A priority patent/JP2024159794A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2020527861A 2017-07-28 2018-07-27 ガラクトース血症を処置するための組成物および方法 Active JP7307059B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022169791A JP7541064B2 (ja) 2017-07-28 2022-10-24 ガラクトース血症を処置するための組成物および方法
JP2024135647A JP2024159794A (ja) 2017-07-28 2024-08-15 ガラクトース血症を処置するための組成物および方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762538443P 2017-07-28 2017-07-28
US62/538,443 2017-07-28
PCT/US2018/044199 WO2019023648A1 (en) 2017-07-28 2018-07-27 COMPOSITIONS AND METHODS FOR TREATING GALACTOSEMIA

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022169791A Division JP7541064B2 (ja) 2017-07-28 2022-10-24 ガラクトース血症を処置するための組成物および方法

Publications (3)

Publication Number Publication Date
JP2020528938A JP2020528938A (ja) 2020-10-01
JP2020528938A5 JP2020528938A5 (https=) 2021-09-09
JP7307059B2 true JP7307059B2 (ja) 2023-07-11

Family

ID=65039851

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020527861A Active JP7307059B2 (ja) 2017-07-28 2018-07-27 ガラクトース血症を処置するための組成物および方法
JP2022169791A Active JP7541064B2 (ja) 2017-07-28 2022-10-24 ガラクトース血症を処置するための組成物および方法
JP2024135647A Pending JP2024159794A (ja) 2017-07-28 2024-08-15 ガラクトース血症を処置するための組成物および方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022169791A Active JP7541064B2 (ja) 2017-07-28 2022-10-24 ガラクトース血症を処置するための組成物および方法
JP2024135647A Pending JP2024159794A (ja) 2017-07-28 2024-08-15 ガラクトース血症を処置するための組成物および方法

Country Status (19)

Country Link
US (2) US11590131B2 (https=)
EP (2) EP3658142B1 (https=)
JP (3) JP7307059B2 (https=)
CN (3) CN119633117A (https=)
AU (2) AU2018307964B2 (https=)
CA (1) CA3071114A1 (https=)
DK (1) DK3658142T3 (https=)
ES (1) ES2983586T3 (https=)
FI (1) FI3658142T3 (https=)
HR (1) HRP20240840T1 (https=)
HU (1) HUE067079T2 (https=)
IL (2) IL272246B2 (https=)
LT (1) LT3658142T (https=)
MX (2) MX2020001057A (https=)
PL (1) PL3658142T3 (https=)
PT (1) PT3658142T (https=)
SG (1) SG11202000730QA (https=)
SI (1) SI3658142T1 (https=)
WO (1) WO2019023648A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL272246B2 (en) * 2017-07-28 2026-01-01 Applied Therapeutics Inc History of 2-(4-oxo/thioketone/azo-3-((substituted)benzo[d]thiazol-2-yl)methyl)- 3,4-dihydrothieno[3,4-d]pyridazin-1-yl)acetic acid for use as an aldose reductase inhibitor for the treatment of galactosemia or prevention of galactosemia-related complications
WO2020173495A1 (zh) * 2019-02-28 2020-09-03 石药集团中奇制药技术（石家庄）有限公司 醛糖还原酶抑制剂的盐及其制备方法和应用
CA3132136A1 (en) * 2019-04-01 2020-10-08 Andrew Wasmuth Inhibitors of aldose reductase
JP2022531466A (ja) 2019-05-07 2022-07-06 ユニバーシティ オブ マイアミ 遺伝性ニューロパチーおよび関連障害の処置および検出
WO2021071965A1 (en) * 2019-10-08 2021-04-15 Applied Therapeutics Inc. Aldose reductase inhibitors for treatment of phosphomannomutase 2 deficiency
WO2021222165A1 (en) * 2020-05-01 2021-11-04 Applied Therapeutics, Inc. Aldose reductase inhibitors for treating sorbitol dehydrogenase deficiency
WO2025104239A1 (en) 2023-11-16 2025-05-22 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of classic galactosemia
WO2025219948A1 (en) * 2024-04-17 2025-10-23 Assia Chemical Industries Ltd. Crystalline forms of govorestat

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016505040A (ja) 2013-01-16 2016-02-18 ザ・トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク アルドース還元酵素阻害剤およびその使用
WO2017223179A1 (en) 2016-06-21 2017-12-28 The Trustees Of Columbia University In The City Of New York Aldose reductase inhibitors and methods of use thereof

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0189272A3 (en) 1985-01-17 1987-08-19 Fujisawa Pharmaceutical Co., Ltd. New furanone derivatives, processes for preparation thereof and use thereof
US4939140A (en) * 1985-11-07 1990-07-03 Pfizer Inc. Heterocyclic oxophthalazinyl acetic acids
CA1299178C (en) * 1985-11-07 1992-04-21 Banavara Lakshmana Mylari Heterocyclic oxophtalazinyl acetic acids
DE3684410D1 (de) 1985-11-07 1992-04-23 Pfizer Heterocyclische oxophthalazinylessigsaeure.
AU7386887A (en) 1986-06-12 1987-12-17 American Home Products Corporation Method of stimulating the immune system with tolrestat;(n-((5 -(trifluoromethyl)-6-methoxy-1-naphthenyl)thioxomethyl)-n-me hylglycine)
US4868301A (en) 1987-06-09 1989-09-19 Pfizer Inc. Processes and intermediates for the preparation of oxophthalazinyl acetic acids having benzothiazole or other heterocyclic side chains
CA1307537C (en) * 1987-12-23 1992-09-15 Jay E. Wrobel N-naphthoylglycines as aldose reductase inhibitors
WO1989006651A1 (en) 1988-01-19 1989-07-27 Pfizer Inc. 1h-indazole-3-acetic acids as aldose reductase inhibitors
US4996204A (en) 1989-05-11 1991-02-26 Pfizer Inc. Pyrido[2,3-d]pyridazinones as aldose reductase inhibitors
US4954629A (en) 1989-05-11 1990-09-04 Pfizer Inc. Process and intermediates for the preparation of oxophthalazinyl acetic acids and analogs thereof
FR2647676A1 (fr) 1989-06-05 1990-12-07 Union Pharma Scient Appl Nouveaux derives de pyridazinone, leurs procedes de preparation, medicaments les contenant, utiles notamment comme inhibiteurs de l'aldose reductase
FI922308A7 (fi) 1989-12-15 1992-05-21 Pfizer Substituoituja oksoftalatsinyylietikkahappoja ja niiden anologeja
JPH0495025A (ja) 1990-08-08 1992-03-27 Asahi Chem Ind Co Ltd アルドースリダクターゼ阻害剤
US5728704A (en) 1992-09-28 1998-03-17 Pfizer Inc. Substituted pyridmidines for control of diabetic complications
US5464961A (en) 1993-09-10 1995-11-07 Olin Corporation Arcjet anode
US5624949A (en) 1993-12-07 1997-04-29 Eli Lilly And Company Protein kinase C inhibitors
TW420669B (en) 1994-03-28 2001-02-01 Nissan Chemical Ind Ltd Pyridine type thiazolidines
JPH11512095A (ja) 1995-08-28 1999-10-19 アメリカン・ホーム・プロダクツ・コーポレイション アルドース還元酵素阻害薬および抗高血糖症薬としてのフェノキシ酢酸
PL179170B1 (pl) 1995-09-15 2000-07-31 Inst Lekow Nowe zwiazki,pochodne genisteiny PL PL PL PL
SI0776895T1 (en) 1995-11-20 1999-04-30 Eli Lilly And Company Protein kinase C inhibitor
US6696407B1 (en) 1997-03-21 2004-02-24 The Regents Of The University Of California Huntington's disease treatment comprising administering aldose reductase inhibitors to increase striatal CNTF
AU9253798A (en) 1997-09-23 1999-04-12 Novo Nordisk A/S Modules of protein tyrosine phosphatases (ptpases)
US6214991B1 (en) 1998-03-31 2001-04-10 The Institute For Pharmaceutical Discovery, Inc. Substituted indolealkanoic acids
EP0982306A3 (en) 1998-08-21 2000-07-05 Pfizer Products Inc. Polymorph of zopolrestat monohydrate
PL350884A1 (en) 1999-04-01 2003-02-10 Pfizer Prod Inc Aminopyrimidines as sorbitol dehydrogenase inhibitors
JP4511655B2 (ja) 1999-08-25 2010-07-28 ユニチカ株式会社 ソルビトール脱水素酵素、それを産生する微生物およびその製造方法
US6916824B1 (en) 1999-11-12 2005-07-12 Kansas State University Research Foundation Methods of treating cataracts and diabetic retinopathy with tricyclic pyrones
EP1106210A3 (en) * 1999-12-07 2003-12-03 Pfizer Products Inc. Combination of aldose reductase inhibitors and antihypertensive agents for the treatment of diabetic complications
US6570013B2 (en) 2000-02-16 2003-05-27 Pfizer Inc Salts of zopolrestat
EP1491541B1 (en) 2001-03-30 2007-01-24 Pfizer Products Inc. Pyridazinone aldose reductase inhibitors
WO2003061660A1 (en) 2002-01-23 2003-07-31 Eli Lilly And Company Melanocortin receptor agonists
WO2003105864A1 (en) 2002-06-13 2003-12-24 Board Of Regents, The University Of Texas System Methods and compositions involving aldose reductase inhibitors
US7410981B2 (en) 2002-06-14 2008-08-12 Takeda Pharmaceutical Company Limited Prodrugs of imidazole derivatives, for use as proton pump inhibitors in the treatment of e.g. peptic ulcers
EP2857036B1 (en) 2003-01-31 2016-12-21 Mount Sinai School of Medicine of New York University Combination therapy for treating protein deficiency disorders
US7572910B2 (en) 2003-02-20 2009-08-11 Pfizer, Inc. Pyridazinone aldose reductase inhibitors
JP5044122B2 (ja) * 2003-10-24 2012-10-10 株式会社明治 後期糖化最終生成物形成の新規阻害剤及びアルドース還元酵素阻害剤
US20070021366A1 (en) 2004-11-19 2007-01-25 Srivastava Satish K Structural-based inhibitors of the glutathione binding site in aldose reductase, methods of screening therefor and methods of use
US20110092566A1 (en) 2004-11-19 2011-04-21 Srivastava Satish K Treatment of cancer with aldose reductase inhibitors
CA2682726C (en) 2007-04-05 2017-05-09 Morphotek, Inc. Methods for inhibiting the binding of endosialin to ligands
CN101143868A (zh) 2007-09-04 2008-03-19 北京理工大学 醛糖还原酶抑制剂结构及用途
EP2065038A1 (en) 2007-11-30 2009-06-03 Pharnext New therapeutic approaches for treating Charcot-Marie-Tooth disease
US20100215726A1 (en) 2009-02-25 2010-08-26 Peter Thomas Roth Compositions for Diminishing the Appearance of Wrinkles
US20130029983A1 (en) 2009-09-23 2013-01-31 Carlo Ballatore Aminothienopyridazine inhibitors of tau assembly
US9494605B2 (en) 2009-11-20 2016-11-15 Pharnext Diagnostic tools for charcot-marie-tooth disease
HRP20221430T1 (hr) 2010-07-16 2023-01-06 The Trustees Of Columbia University In The City Of New York Inhibitori aldozoreduktaze i njihova uporaba
US10060887B2 (en) 2010-11-15 2018-08-28 The United States Of America As Represented By The Secretary Of The Army Field sampling kit and methods for collecting and detecting alkyl methylphosphonic acids
CN102512407B (zh) 2011-11-23 2014-05-21 中山大学 一种β-苯丙氨酸类化合物作为醛糖还原酶抑制剂的应用
WO2013123403A1 (en) 2012-02-15 2013-08-22 Sanford-Burnham Medical Research Institute Theranostics platform and methods of use
GB201205739D0 (en) 2012-03-30 2012-05-16 Ucl Business Plc Treatment of acute inflammation in the respiratory tract
US9921221B2 (en) 2012-07-26 2018-03-20 Joslin Diabetes Center, Inc. Predicting and treating diabetic complications
US20170362237A1 (en) 2016-06-17 2017-12-21 Banavara L. Mylari Water soluble salts of aldose reductase inhibitors for treatment of diabetic complications
CA2904334C (en) 2013-03-15 2024-02-20 Ajay Verma Assessment of labeled probes in a subject
JP6187364B2 (ja) 2014-03-31 2017-08-30 ブラザー工業株式会社 印刷装置
WO2017038505A1 (ja) 2015-09-01 2017-03-09 株式会社村田製作所 コイル内蔵部品
WO2017191274A2 (en) 2016-05-04 2017-11-09 Curevac Ag Rna encoding a therapeutic protein
WO2018090006A1 (en) 2016-11-14 2018-05-17 Memorial Sloan-Kettering Cancer Center Methods for drug discovery using stem cell-derived schwann cells
KR20240116572A (ko) 2017-03-23 2024-07-29 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 핵산 프로그램가능한 dna 결합 단백질을 포함하는 핵염기 편집제
WO2018200258A1 (en) * 2017-04-27 2018-11-01 Applied Therapeutics Inc. Aldose reductase inhibitors and uses thereof
IL272246B2 (en) 2017-07-28 2026-01-01 Applied Therapeutics Inc History of 2-(4-oxo/thioketone/azo-3-((substituted)benzo[d]thiazol-2-yl)methyl)- 3,4-dihydrothieno[3,4-d]pyridazin-1-yl)acetic acid for use as an aldose reductase inhibitor for the treatment of galactosemia or prevention of galactosemia-related complications
US11329472B2 (en) 2018-07-20 2022-05-10 Texas Instruments Incorporated Methods and apparatus to prevent undesired triggering of short circuit or over current protection
AU2019326265B2 (en) 2018-08-20 2025-07-24 Maggie's Pearl, Llc Methods for treating congenital disorders of glycosylation
WO2020167937A1 (en) 2019-02-12 2020-08-20 Applied Therapeutics, Inc. Methods for treating cutaneous aging
CA3132136A1 (en) 2019-04-01 2020-10-08 Andrew Wasmuth Inhibitors of aldose reductase
JP2022531466A (ja) 2019-05-07 2022-07-06 ユニバーシティ オブ マイアミ 遺伝性ニューロパチーおよび関連障害の処置および検出
WO2021071965A1 (en) 2019-10-08 2021-04-15 Applied Therapeutics Inc. Aldose reductase inhibitors for treatment of phosphomannomutase 2 deficiency
EP4125909A1 (en) 2020-03-31 2023-02-08 Applied Therapeutics Inc. Aldose reductase inhibitors for the treatment of acute respiratory distress syndrome, acute lung inflammation/injury, cardiac injury and anti-viral therapy
WO2021222165A1 (en) 2020-05-01 2021-11-04 Applied Therapeutics, Inc. Aldose reductase inhibitors for treating sorbitol dehydrogenase deficiency

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016505040A (ja) 2013-01-16 2016-02-18 ザ・トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク アルドース還元酵素阻害剤およびその使用
WO2017223179A1 (en) 2016-06-21 2017-12-28 The Trustees Of Columbia University In The City Of New York Aldose reductase inhibitors and methods of use thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Exp. Eye Res.，1998年，Vol.66，pp.217-222

Also Published As

Publication number Publication date
EP3658142A4 (en) 2021-06-09
EP4417260A3 (en) 2024-11-20
HUE067079T2 (hu) 2024-09-28
US20200230139A1 (en) 2020-07-23
AU2024200537A1 (en) 2024-02-15
JP2020528938A (ja) 2020-10-01
JP2022188305A (ja) 2022-12-20
CN111065392A (zh) 2020-04-24
IL272246B1 (en) 2025-09-01
BR112020001755A2 (pt) 2020-07-21
AU2018307964A1 (en) 2020-02-13
CN111065392B (zh) 2024-10-25
US20230346782A1 (en) 2023-11-02
CN119633117A (zh) 2025-03-18
CN119971038A (zh) 2025-05-13
LT3658142T (lt) 2024-07-25
PL3658142T3 (pl) 2024-08-26
FI3658142T3 (fi) 2024-07-15
RU2020107188A3 (https=) 2022-04-13
AU2018307964B2 (en) 2023-11-16
ES2983586T3 (es) 2024-10-23
CA3071114A1 (en) 2019-01-31
DK3658142T3 (en) 2024-06-24
SG11202000730QA (en) 2020-02-27
RU2020107188A (ru) 2021-08-30
EP4417260A2 (en) 2024-08-21
JP7541064B2 (ja) 2024-08-27
MX2020001057A (es) 2020-11-24
PT3658142T (pt) 2024-06-27
MX2022015186A (es) 2023-01-24
JP2024159794A (ja) 2024-11-08
EP3658142A1 (en) 2020-06-03
EP3658142B1 (en) 2024-04-17
HRP20240840T1 (hr) 2024-10-11
IL272246B2 (en) 2026-01-01
SI3658142T1 (sl) 2024-09-30
WO2019023648A1 (en) 2019-01-31
IL272246A (en) 2020-03-31
IL322622A (en) 2025-10-01
US11590131B2 (en) 2023-02-28

Similar Documents

Publication Publication Date Title
JP7307059B2 (ja) ガラクトース血症を処置するための組成物および方法
JP7778686B2 (ja) ホスホマンノムターゼ２欠損の処置のためのアルドースレダクターゼ阻害剤
JP7788399B2 (ja) ソルビトールデヒドロゲナーゼ欠乏症を処置するためのアルドースレダクターゼ阻害剤
RU2830187C2 (ru) Композиции и способы лечения галактоземии
HK40113967A (en) Compositions and methods for treating galactosemia
HK40030466B (en) Compositions and methods for treating galactosemia
HK40030466A (en) Compositions and methods for treating galactosemia
BR122025016427A2 (pt) Usos de um inibidor da aldose redutase para o tratamento de galactosemia
RU2858535C2 (ru) Ингибиторы альдозоредуктазы для лечения дефицита сорбитолдегидрогеназы
BR112020001755B1 (pt) Usos de um inibidor da aldose redutase para o tratamento de galactosemia

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200330

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210727

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210727

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220725

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221024

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20221024

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230130

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230501

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230628

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230629

R150 Certificate of patent or registration of utility model

Ref document number: 7307059

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150